Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 349,100 | 139,700 | 396,300 | 251,100 | 293,700 |
| Marketable Securities | 878,900 | 899,200 | 814,300 | 780,500 | 801,400 |
| Receivables | 481,100 | 468,200 | 450,700 | 439,300 | 417,800 |
| Inventories | 45,800 | 42,500 | 37,200 | 38,300 | 28,800 |
| Other current assets | 121,700 | 120,200 | 100,500 | 97,800 | 108,200 |
| TOTAL | $1,876,600 | $1,669,800 | $1,799,000 | $1,607,000 | $1,649,900 |
| Non-Current Assets | |||||
| PPE Net | 80,000 | 80,100 | 75,300 | 70,800 | 68,800 |
| Investments And Advances | 770,600 | 781,400 | 863,900 | 849,400 | 587,500 |
| Intangibles | 34,500 | 33,500 | 34,300 | 35,500 | 34,900 |
| Other Non-Current Assets | 773,300 | 740,200 | 699,900 | 688,700 | 507,100 |
| TOTAL | $1,658,400 | $1,635,200 | $1,673,400 | $1,644,400 | $1,198,300 |
| Total Assets | $3,535,000 | $3,305,000 | $3,472,400 | $3,251,400 | $2,848,200 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 392,700 | 358,500 | 417,200 | 448,800 | 503,000 |
| Other current liabilities | 37,000 | 40,000 | 36,700 | 35,900 | 18,700 |
| TOTAL | $429,700 | $398,500 | $712,900 | $654,800 | $691,600 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 386,400 | 397,300 | 373,400 | 364,600 | 154,500 |
| TOTAL | $386,400 | $397,300 | $373,400 | $364,600 | $154,500 |
| Total Liabilities | $816,100 | $795,800 | $1,086,300 | $1,019,400 | $846,100 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 101,247 | 100,976 | 100,637 | 99,507 | 98,252 |
| Common Shares | 100 | 100 | 100 | 100 | 100 |
| Retained earnings | 81,100 | -48,700 | -113,700 | -157,100 | -304,800 |
| Other shareholders' equity | 14,500 | 2,500 | 3,300 | 7,000 | -1,700 |
| TOTAL | $2,718,900 | $2,509,200 | $2,386,100 | $2,232,000 | $2,002,100 |
| Total Liabilities And Equity | $3,535,000 | $3,305,000 | $3,472,400 | $3,251,400 | $2,848,200 |